Financial Performance - The company's operating revenue for Q1 2022 was CNY 1,910,323,745.74, representing a 50.67% increase compared to CNY 1,267,876,796.45 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was CNY 234,943,371.65, a 63.74% increase from CNY 143,483,266.73 year-on-year[3] - Basic and diluted earnings per share for Q1 2022 were CNY 0.1601, up 63.70% from CNY 0.0978 in the same period last year[3] - The gross profit for the period was RMB 579.2 million, up from RMB 418.0 million year-on-year, reflecting a strong growth in profitability[12] - Net profit attributable to shareholders was RMB 234.9 million, compared to RMB 143.5 million in the previous year, marking a 63.7% increase[12] - The total comprehensive income for the current period was ¥230,706,330.71, compared to ¥150,660,916.07 in the previous period, reflecting an increase of approximately 53.1%[26] Cash Flow - The net cash flow from operating activities was negative CNY 1,378,827.28, a decline of 100.33% compared to CNY 419,806,687.16 in the previous year[3] - The cash flow from operating activities showed a significant decline, with a net outflow of RMB 1,378,827.28 compared to a net inflow of RMB 419,806,687.16 in the same period last year, a decrease of 100.33%[11] - The cash flow from financing activities increased by 747.34%, reaching RMB 616,763,600.63, primarily due to a rise in net borrowings[11] - The cash flow from financing activities generated a net inflow of ¥616,763,600.63, compared to a net inflow of ¥72,788,524.98 in the previous period, indicating a substantial increase[30] - The cash flow from investing activities resulted in a net outflow of ¥88,020,516.24, contrasting with a net inflow of ¥297,313,031.90 in the previous period[29] Operating Costs and Expenses - The company's operating costs for Q1 2022 were CNY 1,331,158,955.65, reflecting a 56.63% increase from CNY 849,901,135.30 year-on-year, primarily due to increased sales volume[9] - Sales expenses increased by 35.67% to CNY 120,294,534.92, attributed to higher marketing costs during the reporting period[9] - Total operating costs for the current period were RMB 1,657,045,547.09, up from RMB 1,129,172,329.84 in the previous period, indicating an increase of about 46.6%[24] Assets and Liabilities - Total assets at the end of Q1 2022 were CNY 20,130,476,736.54, a 5.35% increase from CNY 19,108,175,266.78 at the end of the previous year[3] - Accounts payable increased by 39.43% to CNY 537,885,101.63, mainly due to higher raw material purchases during the reporting period[7] - The company's cash and cash equivalents at the end of the period amounted to RMB 3,471,470,490.96, compared to RMB 2,944,257,086.12 at the beginning of the year, reflecting a growth of approximately 17.9%[20] - Accounts receivable increased to RMB 1,649,294,941.30 from RMB 1,518,444,482.00, marking a rise of about 8.6%[20] - Inventory levels rose to RMB 5,064,439,320.27 from RMB 4,707,548,592.43, which is an increase of approximately 7.6%[20] - Current liabilities increased to RMB 5,732,113,230.57 from RMB 4,791,469,653.07, representing a growth of approximately 19.7%[22] Market and Strategic Initiatives - The company plans to continue expanding its market presence and enhancing its sales capabilities, particularly in Europe and the US, to offset challenges from geopolitical tensions[13] - The company aims to steadily increase core business sales while capitalizing on favorable raw material prices to significantly improve performance[15] - The company plans to enhance internal collaboration and accelerate the construction of financial and human resource shared centers, as well as the digital transformation of marketing strategies[15] - The company is committed to improving global supply chain efficiency and management, continuously enhancing quality and optimizing costs[15] - The company will actively strengthen its R&D capabilities and connect with global innovative drug development to promote the expansion of its innovative drug field[15] - The company will continue to focus on international market strategies, particularly in Europe, the United States, and non-European and American markets, while actively supporting the normalization of development in the Chinese market[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 29,871, with the top ten shareholders holding a combined 82.76% of shares[16] - Shenzhen Le Ren Technology Co., Ltd. held 32.31% of shares, while Urumqi Jintian Soil Equity Investment Partnership held 27.81%[16] Bond Issuance - The company plans to issue bonds to professional investors with a total scale not exceeding RMB 1.5 billion, which was approved by the board on December 10, 2021[19] - The bond issuance was registered and approved by the China Securities Regulatory Commission in March 2022, with listing on the Shenzhen Stock Exchange on April 8, 2022[19] Other Financial Metrics - The company recorded a net loss of RMB 4,532,878.12 in other comprehensive income, a significant decrease of 156.78% compared to a net gain of RMB 7,983,011.63 in the same period last year[10] - The company reported a foreign exchange loss of ¥9,741,485.63, compared to a loss of ¥20,528,526.49 in the previous period, indicating an improvement in foreign exchange impact[30] - The first quarter report has not been audited[31]
海普瑞(09989) - 2022 Q1 - 季度财报